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Clearance of disseminated Salmonella infection requires bacterial-specific Th1 cells and
IFN-c production, and Th1-promoting vaccines are likely to help control these infections.
Consequently, vaccine design has focused on developing Th1-polarizing adjuvants or Ag
that naturally induce Th1 responses. In this study, we show that, in mice, immunization
with soluble, recombinant FliC protein flagellin (sFliC) induces Th2 responses as evidenced
by Ag-specific GATA-3, IL-4 mRNA, and protein induction in CD62Llo CD41 T cells without
associated IFN-c production. Despite these Th2 features, sFliC immunization can enhance
the development of protective Th1 immunity during subsequent Salmonella infection in an
Ab-independent, T-cell-dependent manner. Salmonella infection in sFliC-immunized mice
resulted in augmented Th1 responses, with greater bacterial clearance and increased
numbers of IFN-c-producing CD41 T cells, despite the early induction of Th2 features to
sFliC. The augmented Th1 immunity after sFliC immunization was regulated by T-bet
although T-bet is dispensable for primary responses to sFliC. These findings show that there
can be flexibility in T-cell responses to some subunit vaccines. These vaccines may induce
Th2-type immunity during primary immunization yet promote Th1-dependent responses
during later infection. This suggests that designing Th1-inducing subunit vaccines may not
always be necessary since this can occur naturally during subsequent infection.
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Introduction
Vaccination has been a major factor in improving life-expectancy
through inducing effective Ab and/or T-cell-mediated immunity.
Licensed vaccines are usually one of the three types: inactivated
whole pathogen; live, attenuated organism, or subunits of the
pathogen. All three can be given alone or in the presence of adjuvant.
There are no licensed vaccines for use in humans against
nontyphoidal Salmonella infections such as those caused by
Salmonella enterica serovar Typhimurium (STm), despite it being a
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leading cause of death in infants in regions such as sub-Saharan
Africa [1]. On the contrary, there are three distinct vaccines that offer
good but limited protection against typhoid, caused by Salmonella
enterica serovar Typhi (ST) [2–4]. While killed vaccine is rarely used
because of its toxicity, live attenuated Ty21a vaccine and purified
capsular polysaccharide Vi Ag, confer protection against typhoid in
adults. Importantly, they indicate that multiple Ag and mechanisms
can be used to protect against Salmonella infections. Thus, ST Ty21a
induces potent systemic and mucosal T- and B-cell responses [5],
whereas purified Vi Ag induces T-independent serum Ab, but poor
mucosal responses [4]. Significantly, despite lacking Vi Ag and LPS
O-chain Ty21a can protect against typhoid and thus other Ag may be
useful in subunit vaccines [6].
Salmonella infections can be modelled effectively in the mouse
[7, 8] but to study adaptive immunity to Salmonella in susceptible
mouse strains (e.g. C57BL/6 or BALB/c), attenuated bacterial
strains are commonly used. Clearance of primary infections
requires IFN-g and T-bet-regulated differentiation of CD41 T cells
to Th1 [9–14]. In contrast, B cells and CD81 T cells are not
required to clear primary infections, although Ab can both
moderate bacteremia and help protect against reinfection
[9, 15–18]. Mouse models allow candidate vaccines to be tested
for their potential to protect against Salmonella infections and
enables analysis of the mechanisms by which they protect. Thus,
we recently showed that Ab to OmpD, absent in ST, can inhibit
infection [19, 20] in a T-independent manner.
A common feature of Vi Ag and OmpD is that they are cell
surface localized. Another surface-exposed Ag is flagellin. In STm,
there are two flagellin genes, fliC and fljB, and cells may express
one or other of these genes but not both concurrently. Flagellin
interacts with the immune system directly through at least two
pathways [21–23]: through TLR5 or via recognition by NOD-like
receptor NLRC4. The impact of flagellin on the innate immune
system is profound and includes the induction of cytokines from
multiple cell types, DC maturation, and adaptive responses to
itself and coadministered Ag [24–31].
The capacity of bacterial flagellin to be both a target of the
immune response and an adjuvant are well reported [25, 26,
32–35]. More surprising is that, although it is a TLR ligand, it
provokes T- and B-cell responses with a strong Th2 bias to itself
and coadministered Ag [25–27, 29]. Nevertheless, isotype
switching to flagellin when surface attached to STm is Th1
reflecting [25]. Thus, the direction of the in vivo response to
flagellin is influenced by the context that the Ag is encountered by
the host immune system.
In this study, we have assessed how the immune response to
soluble, recombinant FliC protein flagellin (sFliC) affects subse-
quent STm infection. Primary immunization with sFliC induces
Th2 responses. Nevertheless, when sFliC-immunized mice are
challenged they show enhanced T-cell-dependent, Ab-indepen-
dent resistance to STm infection. This is because prior sFliC
immunization augments the numbers of IFN-g-producing Th1
cells during subsequent STm infection via a T-bet-regulated
mechanism. The broad significance of this study is that although
sFliC drives a clear Th2 response it still primes for enhanced
T-cell-mediated protection during subsequent STm infection. This
provides an example of a beneficial flexibility in the direction of
T-cell-mediated help induced by a subunit vaccine.
Results
Soluble flagellin induces Th2 responses during
primary immunization
To test whether the CD41 T-cell response to soluble flagellin is
Th2, we examined responses in WT and transgenic, flagellin-
specific SM1 CD41 T cells [36]. First, CFSE-labeled, SM1 CD41
T cells were adoptively transferred into WT mice to compare the
kinetics of the response post-immunization with sFliC or STm.
Almost, all splenic SM1 CD41 T cells had undergone four or more
rounds of division by 48 h in chimeras immunized with sFliC,
whereas 80–90% of the transferred cells from those infected with
STm had completed between one and four cell cycles. The SM1
CD41 T cells in both groups of immunized chimeras showed an
activated profile as assessed by induced CD69 expression and loss
of CD62L (Fig. 1A).
Th features induced by sFliC or STm were then assessed 4–7
days after immunization, depending on the experiment. Real-time
RT-PCR was used to assess gene expression in total CD41
T cells from nonimmunized (NI) WT mice or after sFliC or STm in
WT or SM1 CD41 T cells sorted into CD62Llo (effector) or CD62Lhi
(noneffector) subsets. These experiments show that CD62Llo effec-
tor T cells from sFliC-immunized mice had upregulated GATA-3 and
IL-4 mRNA compared with STm-infected mice. On the contrary, IL-4
mRNA was largely undetectable in the absence of sFliC immuniza-
tion (Fig. 1B). IFN-g and T-bet mRNA levels were consistently
higher after STm infection than in NI mice or sFliC-immunized
mice. While some expression of IFN-g and T-bet mRNA was seen in
CD62Llo effector T cells after sFliC, levels were approximately
10–100-fold lower than in CD62Llo effector T cells from STm-
immunized mice. IL-17 mRNA expression was not detected in any
population under any condition (data not shown). To confirm that
IL-4 mRNA induction reflected IL-4 protein production, we
performed ELISPOT analysis on sFliC-restimulated endogenous or
SM1 T cells from NI mice or STm- or sFliC-immunized mice (Fig.
1C). This showed that in both endogenous and transgenic T cells
there was a marked increase in IL-4 spot-forming cells (SFC) after
sFliC, but not STm. This indicates that sFliC immunization induces
IL-4 mRNA and protein-producing cells.
Next, we examined IFN-g production 7 days after immuniza-
tion with sFliC or STm by intracellular FACS staining after
restimulation with anti-CD3 or sFliC. We found that sFliC, unlike
STm, fails to induce IFN-g production in WT CD41 T cells. As
seen previously [37], IFN-g production after STm was found in
CD62Llo WT T cells (Fig. 2A). Similar results were observed in
SM1 T cells from chimeras, with IFN-g induced after STm but to
much lower levels after sFliC (Fig. 2A). Restimulation with sFliC
rather than anti-CD3 Ab showed similar results, except that in WT
cells IFN-g levels were half those after anti-CD3 stimulation,
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reflecting previous reports [34, 38]. ELISPOT experiments for
IFN-g secretion confirmed that intracellular IFN-g protein
production reflected protein secretion (data not shown). After
sFliCo1% of splenic CD41 T cells responding to sFliC produced
IL-17 or TNF-a protein and there were only small changes in
T-cell proportions expressing FoxP3 or BCL-6 (data not shown).
Next, we assessed whether the low proportion of IFN-g-producing
T cells induced by sFliC reflected levels induced in WT and OVA-
specific OTII CD41 T cells after immunization with the model Th2
Ag alum-precipitated OVA (Fig. 2B). Similar levels of IFN-g were
induced in WT or OTII cells from WT-OTII chimeras by alum-
precipitated OVA as by sFliC, showing that the levels of IFN-g
induced by sFliC are no greater than those induced to other Th2
Ags. To assess whether the poor IFN-g responses induced to sFliC
simply reflected the use of monomeric sFliC, WT mice were
immunized with polymeric flagellar filaments isolated from the
surface of STm, which failed to promote IFN-g production
(Fig. 2C). The transcription factor T-bet is required for Th1
development [39]. Assessment of its expression showed that STm
but not sFliC induced its induction in endogenous CD41 T cells 7
days after immunization (Fig. 2D). It was possible that sFliC
selectively induced IFN-g in sites other than the spleen, such as
the MLN. To assess this, we performed an ELISPOT assay
on WT T cells in the MLN 5 days after immunization with sFliC
(Fig. 2E). This showed that IL-4, but not IFN-g-secreting,
cells could be readily detected after sFliC immunization. Finally,
IFN-g-producing cells after sFliC immunization did not appear






Figure 1. Soluble flagellin induces Th2 responses. (A) Splenocytes (107) from transgenic flagellin-specific SM1 mice were CFSE-labeled before
adoptive transfer into WT mice. Chimeras were either NI or after 24 h received i.p. 5 105 STm or 20 mg sFliC for 48 h before splenic SM1 CD41 T-cell
division and activation was assessed by CFSE dilution and CD69 or CD62L expression. FACS plots are representative of three experiments.
(B) Graphs show relative mRNA expression per cell (mean1SD) for GATA-3, IL-4, IFN-g, and T-bet by real-time RT-PCR on FACS-sorted NI CD41
T cells (gray bars), CD62Lhi CD41 T cells (black bars), or CD62Llo CD41 T cells (white bars) from WT mice (sorted on CD3, CD4, and CD62L expression;
top panels) or SM1/Rag1-deficient chimeras (gated on CD3, CD4, and CD62L expression; all T cells are SM1 cells; bottom panels) that received
5105 STm or 20mg sFliC for 4 days i.p. (C) Splenocytes from NI WT mice or Rag1 SM1 chimeras, or WT mice or Rag1 SM1 chimeras immunized
with STm or sFliC for 5 days were isolated and restimulated for 48 h before the numbers of IL-4 SFC were enumerated by ELISPOT. Graph shows
mean1SD. Nd, not detected; pr00.05 by the Mann–Whitney test. In all panels, data are representative of Z2 experiments.
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Figure 2. Immunization with soluble flagellin fails to induce IFN-g or T-bet. (A) Representative FACS plots of intracellular IFN-g production after
restimulation with anti-CD3 Ab or sFliC in total WT CD41 T cells (top two rows) or WT T cells subdivided by CD62L expression (middle two rows) or
SM1 CD41 T cells from SM1/WT chimeras (gated on vb2: bottom two rows) given 5105 STm or 20mg sFliC i.p. for 7 days. (B) Representative FACS
plots of intracellular IFN-g production in OTII cells from chimeras (gated on CD45.1) or WT CD41 T cells given 5105 STmOVA or 50mg alum-
precipitated OVA i.p. for 7 days. (C) Representative FACS plots of intracellular IFN-g production after restimulation of WT CD41 T cells from mice
given 5 105 STm or 20 mg surface-purified flagella i.p. for 7 days with anti-CD3 Ab or sFliC. (D) Representative FACS plots of T-bet expression in WT
CD62Lhi and CD62Llo CD41 T cells from NI mice or mice given 5 105 STm or 20mg sFliC i.p. for 7 days after restimulation with anti-CD3 Ab or sFliC.
(E) MLN from NI WT mice, or WT mice immunized with STm or sFliC for 5 days were isolated and restimulated with sFliC for 48 h before IL-4 or
IFN-g SFC were enumerated by ELISPOT. The graph shows mean1SD from one of the two independent experiments; four mice per group.
(F) Representative FACS of intracellular IFN-g production in WT total CD41 T cells given 5 105 STm or 20 mg sFliC i.p. for 35 days. In all cases, FACS
plots are representative of Z2 independent experiments with four mice per group.
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days after immunization (Fig. 2F). The data shown in Figs. 1 and
2 indicate that soluble flagellin induces Th2 responses in vivo,
with GATA-3 upregulation and pronounced IL-4 mRNA produc-
tion, but poor IFN-g and T-bet induction.
Immunization with soluble flagellin promotes clear-
ance of STm at discrete stages of infection
Since flagellin induces Th2 immune responses (Fig. 1), we
assessed whether immunization with sFliC could restrict subse-
quent systemic STm infection. To do this, we immunized WT
mice with 20 mg sFliC for 35 days before infecting i.p. with
5 106 STm and assessed splenic bacterial numbers 5, 18, and 35
days later. This showed that while sFliC conferred no benefit in
controlling splenic STm infection on day 5 after infection there
was an approximate 90% reduction in bacterial numbers by day
18 after infection and significant, but somewhat smaller,
differences in bacterial burdens on day 35 after infection
(Fig. 3). To examine whether systemic sFliC immunization
promoted mucosal immunity, mice were i.p. immunized with
20 mg sFliC for 35 days before oral challenge with 109 STm and
bacterial colonization of the MLN and spleen assessed 2 days
later. This showed that there was a small trend toward lower
colonization of these tissues after sFliC immunization but this
was not significant, despite groups containing at least seven mice
(Fig. 3). Therefore, despite inducing Th2 responses, immuniza-
tion with sFliC accelerates bacterial clearance after the first week
of subsequent infection with STm.
Ab to sFliC fails to protect against STm infection
We have recently shown that Ab to heat-killed or subunit vaccines
against STm is effective by day 5 after infection [19]. The similar
bacterial numbers in NI and sFliC-immunized mice on day 5 after
infection suggest that Ab to sFliC does not inhibit bacterial
colonization. We used a number of approaches to test this.
First, we confirmed [25] that sFliC or surface-isolated flagella
immunization resulted in sustained IgG1 and IgG2a responses
(Fig. 4A). Ab to sFliC was then tested to see if it could impair the
motility of STm through agar. C-inactivated serum from an
individual NI or sFliC-immunized mouse was added to an agar
plate before bacteria were added and bacterial motility
measured. Bacteria had impaired motility through agar that
contained sFliC-specific serum relative to those containing sera
from NI mice (Fig. 4B). Next, bacterial numbers were assessed in
WT and B-cell-deficient mice primed with 20 mg sFliC 35 days
before infection with 5106 STm (Fig. 4C). Five days later, WT
and B-cell-deficient mice had similar levels of bacteria irrespec-
tive of whether they had been immunized with sFliC. We have
previously shown [18, 19] that porins or STm induce Ab that can
markedly reduce the number of STm that colonize the spleen.
STm were incubated with C-inactivated anti-sFliC Ab, or anti-
porin Ab, or anti-STm Ab immediately prior to i.p. infection into
naı¨ve mice (Fig. 4D). Although opsonization with anti-total STm
or porin Ab markedly decreased bacterial colonization [18, 19],
opsonization with anti-sFliC Ab did not. Finally, we examined
whether the ability of STm to phase switch their flagellin
expression accounts for this lack of benefit from sFliC immuni-
zation. To test this, WT mice were immunized with 20 mg sFliC for
35 days and infected for 5 days with 5105 STm or STm that
express only FliC or FljB (Fig. 4E). FljB-locked STm bacterial
numbers were not reduced after sFliC immunization but FliC-
locked STm numbers were approximately tenfold lower. To
exclude the possibility that FliC-locked bacteria were intrinsically
more susceptible to killing by innate mechanisms, we infected
T- and B-cell-deficient Rag1-deficient mice. This shows that all
strains colonized equally well (Fig. 4E). Therefore, Ab to sFliC
induced after immunization can restrict bacterial motility but not
systemic bacterial colonization, partly through a capacity of STm
to phase switch their flagella.
Enhanced bacterial clearance after sFliC correlates
with increased IFN-c-producing CD41 T cell numbers
Since Ab to sFliC did not moderate infection, we next assessed
whether the protection afforded by sFliC immunization on day 18
post-infection (Fig. 3 and Fig. 5A) was T-cell mediated. First, it
was confirmed that T cells are not important for controlling STm
infection in the first week of infection, but are necessary
subsequently, by infecting WT and T-cell-deficient mice with
105 STm for 5 and 18 days (Fig. 5A). As expected [9, 19, 40, 41],
on day 5 after infection both groups had similar splenic bacterial
burdens, whereas at day 18 WT mice had significantly fewer
bacteria than T-cell-deficient mice. It is not likely that the benefits
of sFliC immunization were due to direct effects on the innate
immune system since bacterial numbers in NI and sFliC
immunized Rag1-deficient mice were similar on days 5 and day
18 after STm (Fig. 5B). Furthermore, infection of WT and T-cell-
Figure 3. Flagellin immunization promotes clearance of STm after the
first week of infection. Left panel, WT mice, NI or immunized i.p. with
20 mg sFliC for 35 days were infected i.p. with 5 106 STm for 5, 18, or 35
days and splenic bacterial numbers enumerated. Right panel, WT
mice, NI, or immunized i.p. with 20 mg sFliC for 35 days were infected
orally with 109 STm for 2 days and MLN and splenic bacterial numbers
enumerated. pr00.05 by the Mann–Whitney test. Graphs show mean
bacterial numbers1SD. Data are representative of Z2 experiments at
each time point with Z4 mice in each group.
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deficient mice with or without sFliC immunization for 35 days
showed that T cells were important for the additional control of
infection afforded by sFliC immunization at day 18 post-infection
(Fig. 5B). In contrast, when these experiments were performed
only to day 5 after infection bacterial burdens were similar in WT
and T-cell-deficient mice independent of sFliC immunization
(data not shown). Since clearance of STm requires IFN-g, we
assessed how previous sFliC immunization altered IFN-g produc-
tion in CD41 T cells during subsequent infection. At day 5 after
infection, proportions and numbers of IFN-g producing CD41
T cells were lower in sFliC-immunized mice (Fig. 5C). Never-
theless, when responses were assessed after 18 days of infection,
the sFliC-immunized group had a higher proportion and number
of IFN-g1CD41 T cells, with IFN-g only detectable in CD62Llo
CD41 T cells (Fig. 5C). By day 35, when infection has nearly
resolved in both groups, the numbers and proportions of IFN-g1
CD41 T cells in both groups were similar. These results were
unlikely to be influenced by IL-4 since ELISPOT failed to identify
the differences in immunized and NI groups on day 5 after
infection and IL-41 SFC were largely undetectable at day 18 after
infection (Fig. 5D). Thus, under these conditions immunization
with the Th2 Ag sFliC can promote Th1 responses.
T-bet is essential for enhanced bacterial clearance and
IFN-c production after sFliC immunization
Since sFliC enhanced IFN-g responses to STm, we wished to
assess how this was mediated. While antibody to sFliC did not
help control infection at day 5 of infection, it remained possible
that B cells and antibody contributed by day 18 when the benefit




Figure 4. Flagellin induces potent Ab responses which fail to impair STm infection. (A) Serum FliC-specific IgG1 and IgG2a Ab titers induced 35
days after 20mg sFliC (left graph) or 20mg surface-purified flagellin (right graph) i.p immunization. (B) Radius of bacterial swimzones after
swimming through 0.3% agar containing C-inactivated sera from naı¨ve mice (NI) or mice immunized twice with sFliC (four sera/group). (C) Splenic
bacterial numbers in NI or sFliC-immunized (20 mg for 35 days) WT or B-cell-deficient (IgH/) mice infected for 5 days i.p. with 5 106 STm.
(D) Splenic bacterial counts after i.p. infection for 5 days with 5105 STm opsonized with C-inactivated NI sera, or anti-sFliC sera (14 days post-
boosting), or anti-porin sera, or anti-STm sera. (E) Left graph: Splenic bacterial numbers in WT mice immunized for 35 days with 20 mg sFliC before
infection with 5106 STm or FliCFljB1 STm (only express FljB) or FliC1FljB STm (only express FliC). Right graph: Splenic bacterial numbers from
Rag1-deficient mice infected i.p. with 5 105 of each strain for 7 days. Graphs show mean1SD; groups contain Z4 animals, sera, or bacterial
cultures. Nd, not detected. pr00.05 by the Mann–Whitney test. Experiments are representative of Z2 repeats in each case.
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deficient mice for 35 days before infection with 5 105 STm and
examined splenic bacterial numbers and levels of IFN-g produc-
tion 18 days later (Fig. 6A). This showed that the absence of
B cells and antibody did not influence bacterial clearance or IFN-g
responses by CD41 T cells, irrespective of whether mice had been
immunized with sFliC. These experiments were repeated using
IL-4Ra-deficient mice and showed that signaling through IL-4Ra
was dispensable for the sFliC-mediated control of infection or to
IFN-g production (data not shown). Next, we assessed whether











Figure 5. Enhanced bacterial clearance after sFliC immunization correlates with augmented numbers of IFN-g producing CD41 T cells. (A) Left
graph: splenic bacterial numbers in naı¨ve (NI) or sFliC-immunized mice infected for 35 days. Right graph: Splenic bacterial counts from WT and
T-cell-deficient (TCRbd/) mice infected i.p. with 5 105 STm for 5 and 18 days. (B) Left graph: Splenic bacterial counts in NI or sFliC-immunized
(20 mg; i.p. for 7 days) Rag1-deficient mice infected i.p. with 5105 STm for 7 or 18 days. Right graph: Splenic bacterial numbers in NI or sFliC-
immunized (20 mg for 35 days) WT or T-cell-deficient mice infected for 18 days i.p. with 5 106 STm. (C) Representative FACS plots showing
intracellular IFN-g production, after anti-CD3 stimulation with anti-CD28, in total splenic CD41 T cells or subdivided by CD62L expression in NI or
sFliC-immunized (20 mg for 35 days) WT mice infected i.p. with 5 105 STm for either 5, 18, or 35 days. Proportion (left graph) and total numbers
(right graph) of IFN-g-producing splenic CD41 T cells. (D) Splenocytes from NI or sFliC-immunized WT mice infected with STm for 5 or 18 days
were isolated and restimulated for 48 h before the numbers of IL-4 SFC were enumerated by ELISPOT. Graphs show mean and one SD. Groups
contained four mice and experiments are representative of Z2 repeats. pr00.05 by the Mann–Whitney test.
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Th1 regulator T-bet despite sFliC not inducing T-bet (Fig. 2). To
confirm that T-bet was required for bacterial clearance at the day
18 time point [12], when sFliC promotes bacterial clearance, we
infected WT and T-bet-deficient mice with 5105 STm and
found bacterial numbers were higher in the absence of T-bet and





Figure 6. T-bet is required for promoting Th1-mediated clearance after sFliC immunization but not for the induction of Th2 responses. (A) Splenic
bacterial numbers (left) and proportions of IFN-g1 splenic CD41 T cells in NI or sFliC-immunized (20 mg for 35 days) WT or B-cell-deficient (IgH/)
mice infected for 18 days i.p. with 5 106 STm. (B) WT and T-bet-deficient mice were infected i.p. with 5105 STm for 18 days and splenic bacterial
numbers enumerated (left graph) and intracellular IFN-g production by splenic CD41 T cells assessed, shown as representative FACS panels and
right graph. (C) NI WT or NI or sFliC-immunized (20 mg for 35 days) T-bet-deficient mice were infected i.p. with 5 105 STm for 18 days. Splenic
bacterial numbers (left) and IFN-g production by CD41 T cells was assessed by intracellular FACS in CD41 T cells (anti-CD3 stimulation with anti-
CD28; centre and right). Groups contained four mice. (D) Left: IL-4 mRNA expression in FACS-sorted splenic WT and T-bet-deficient CD62Lhi and
CD62Llo CD41 T cells mice 4 days after i.p. immunization with 20mg sFliC, CD4 T cells from NI mice had negligible IL-4 mRNA levels (data not
shown). Serum anti-FliC IgM 7 days (centre) or IgG and isotypes 35 days (right) from WT and T-bet-deficient mice assessed by ELISA. Graphs show
mean and one SD.pr00.05 by the Mann–Whitney test. In all cases, experiments are representative of Z2 repeats.
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(Fig. 6B). To assess whether T-bet was required for the action of
sFliC, NI or T-bet-deficient mice immunized with 20 mg sFliC for
35 days were infected with 5 105 STm for 18 days. Priming with
sFliC did not confer any benefit against STm infection in T-bet-
deficient mice and IFN-g production was absent in both sets of
mice (Fig. 6C). Thus, the Th2 Ag sFliC enhances STm clearance in
a T-bet-mediated manner. Finally, we examined whether this was
because T-bet was required for the induction of responses to
sFliC. To do this, WT or T-bet-deficient mice were immunized for
4, 7, or 35 days and IL-4 mRNA production assessed in FACS-
sorted splenic CD41 T cells or serum anti-FliC IgM or IgG
assessed by ELISA, respectively. This shows that T-bet was not
required for the induction of responses to sFliC (Fig. 6D).
Therefore, sFliC induces T-bet-independent Th2 features but
requires T-bet to promote STm clearance.
Discussion
By examining immune responses to flagellin, its use as an
immunogen and its impact on subsequent infection, we have
examined how isolated STm proteins may function as vaccines
against STm infection. While sFliC induces potent humoral and
cellular immune responses, only cellular immunity was able to,
modestly, help control infection. Against expectations, we found that
although sFliC induced a primary Th2 response, it could promote
Th1-mediated protection that was apparent after the first week of a
subsequent STm infection. This suggests that the Th response to
sFliC, and by implication other subunit vaccines, can be flexible.
Directing the immune response to an Ag has been a significant
focus of research, particularly for adjuvants, because the type of T-
cell help initially induced to an Ag can indicate whether the Ag will
confer protection. The absolute need for this is challenged by our
findings, which suggest that under some circumstances this may
not be necessary. The Th2 responses induced to sFliC in vivo
develop in the absence of exogenous adjuvants. Few purified
proteins have autoadjuvant activity, with proteins such as flagellin,
tetanus toxoid, and pertussis toxin having this property. In mice
and humans, the responses to these Ag are predominantly Th2 [25,
26, 42, 43] and suggests responses to soluble proteins are likely to
be Th2 by default. Nevertheless, the observation that subsequent
STm infection resulted in an enhanced Th1 response suggests that
T-cell responses show some flexibility. In most instances though,
the direction of the Th response may be of secondary importance if
protective Ab responses are induced.
The increased numbers of Th1 cells seen after infection of sFliC-
primed mice could result from the redirection of Th2 cells
to Th1 [44] or derive from primed, yet nondifferentiated T cells [42,
44, 45] or other primed subsets such as IL-17 producing, FoxP3, or
BCL61 follicular helper T cells [46]. Th2 differentiation to sFliC was
the dominant response detected, for there were only low levels of
IFN-g, T-bet, IL-17 (r0.1% of CD41 T cells), BCL6, or FoxP31
T cells detected (Fig. 2 and data not shown). It was recently found
that LCMV-specific in vitro-primed Th2 cells can redirect to Th1 in
vivo and produce IFN-g in a T-bet-dependent manner [47]. This
important finding shows flexibility in the Th response and the
current study augments this by showing that redirection can also
occur after immunization. Nevertheless, we suggest that our in vivo
findings are also likely to mean that primed, but noncommitted,
CD41 T cells act as a reservoir from which the enhanced Th1
responses after STm infection of sFliC-immunized mice are derived.
This T-cell flexibility after infection of vaccinated animals has been
described in other systems [42, 45]. Surprisingly, the Th1 expansion
after sFliC immunization required T-bet, despite primary CD41 T-cell
responses to sFliC being T-bet-independent and T-bet not being
required to control other infections [48]. This had suggested to us
that the Th1 augmentation after sFliC would be T-bet-independent.
Ab to sFliC was not protective in these studies, in part because
STm can phase-switch. Nevertheless, splenic bacterial numbers in
sFliC-immunized mice after infection with FliC-locked STm were
only modestly reduced, typically o1 log of protection, a level
similar to that mediated by CD41 T cells at later times. In
contrast, effective Ab protection can reduce bacterial numbers by
several orders of magnitude [19], and Ab to Salmonella is clearly
important at preventing infection in humans and mice [16, 19,
49–54]. Immunization with sFliC provided no significant, early,
protection against oral infection with STm although there was a
trend toward protection seen in the large groups of mice used for
these experiments. This suggests that mucosal anti-sFliC respon-
ses while probably having some role are not likely to make a
substantial impact on controlling early colonization, at least after
one immunization with sFliC. The lack of protection by Ab to
flagellin in the mouse reflects findings using human sera [54],
where antibodies to flagellin had no clear, protective capacity.
Thus, structures distal from the cell wall such as flagella may not
be efficient targets for Ab-mediated protection. Intriguingly,
although binding of flagellin by sFliC-specific sera could inhibit
motility, it did not result in shedding or loss of flagella (Fig. 4B
and data not shown), suggesting that the bacterium does not
necessarily shed flagella when antibody has bound. Thus, Ab to
flagellin does not have a significant role in protecting against
systemic infection in this model.
Immunity to STm after systemic immunization with flagellin
has been described previously [34, 55, 56]. In our experiments,
we have focused on how this limited protection is mediated.
While this benefit is Ab-independent, CD41 T cells are important,
but only after the first week of infection. This has two implica-
tions. First, since there was no early benefit after sFliC immuni-
zation, it suggests that T cells in recall responses do not promote
accelerated bacterial clearance after STm infection, a finding we
have also seen after porin immunization [19]. A consequence of
this is that it suggests that sFliC immunization will confer no
significant protection against virulent strains of bacteria since its
contribution to immunity is made when infection is well estab-
lished. Second, it suggests that there is some bioavailability of
flagellin throughout infection. While flagellin synthesis, expres-
sion, and availability are suppressed during intracellular infection
[38, 57, 58], this may not be absolute [59, 60]. Nevertheless, it is
unclear whether the modest T-cell-mediated protection after
flagellin immunization is because CD41 T cells induced after
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immunization are not efficient at promoting bacterial killing or
whether only a proportion of infected cells contain flagellin-
expressing bacteria. Flagellin phase-switching is unlikely to
promote immune evasion of T-cell responses since T-cell epitopes
are found in conserved regions of FliC and FljB [32, 34, 38, 36],
some of which are found in other serovars such as Salmonella
enteritidis. This may mean that some T cells after immunization
with sFliC will recognize multiple Salmonella serovars.
An important question is why the rate of clearance of atte-
nuated bacteria progresses at a protracted rate in the face of
potent CD41 T-cell responses, where massive Th1 expansion
occurs rapidly after infection [37, 61]? This may mean it is
unwise to focus simply on vaccines that evoke CD41 T-cell-
mediated immunity in the absence of protective Ab responses. Ab
is likely to reduce the numbers of bacteria that colonize, resulting
in a lower peak bacterial burden, essentially affording more time
for Th1 cells to clear tissue-residing bacteria. Is flagellin simply
just a bad choice of Ag for a vaccine? It is not optimal against
systemic infection as it fails to induce protective antibody
responses, and the benefits from enhanced Th1-cell-mediated
immunity are modest. An ideal subunit vaccine should offer both
humoral and cellular protection. This may require the generation
of subunit vaccines that have more than one component, each
contributing protection via humoral or cell-mediated immunity
or both. Live STm have this property, but balancing immuno-
genicity and toxicity is difficult, and attenuated vaccines may not
be effective in certain groups such as infants or those with
acquired immunodeficiencies. Whether other T-cell Ag (e.g. [62])
are better remains to be seen since their potential to induce
protective Ab needs to be carefully evaluated.
Materials and methods
Mice, bacterial strains, and immunogens
Mice were age (6–12 wk) and sex matched. C57BL/6 mice were
from HarlanOLAC and SM1 transgenic mice [36] were from Paul
Garside with generous permission from Stephen McSorley. OTII
transgenic, TCRbd-, Rag1-, B-cell-, and T-bet-deficient mice [39]
were sourced in-house. Animal studies were performed with
ethical and Home Office approval.
STm SL3261 is an attenuated strain and OVA-expressing
SL3261 has been described previously [63]. fliCfljB1 and fliC1
fljB strains were generated by P22 transduction of the kana-
mycin resistance gene from SL3201ON and SL3201OFF into
SL3261 (SL3201 strains kindly provided by Dr. Alison O’Brien,
Uniformed Services University of the Health Sciences; [64]).
FliC and whole flagella were isolated and purified [25] as an
immunoprecipitated, his-tagged recombinant protein or from
STm by acid hydrolysis [65] and size-exclusion chromatography.
OVA was alum precipitated by standard methods [63]. LPS
contamination was typicallyo1 endotoxin unit/300 mg protein
(Sigma Endotoxin Kit).
Immunizations, infections, and opsonization of
bacteria
Mice received, i.p., 20 mg sFliC or 50 mg alum-precipitated OVA or
live bacteria (5 105–5 106/mouse in PBS from cultures
harvested at OD60051.2–1.4). Tissue bacterial burdens were
determined by direct culturing. Murine infections using opso-
nized bacteria were performed as described previously [18, 19],
using complement-inactivated sera from WT mice immunized
twice with sFliC (boosted at 35 days for 14 days). Viability and
lack of agglutination was confirmed by plating. For oral infection,
STm (1010/mL) were diluted at a ratio of 1:1 with 3% NaHCO3
and mice immediately infected with 1 109 bacteria by oral
gavage.
Bacterial motility assay
Bacterial swimming was assessed using 0.3% agar containing
complement-inactivated naı¨ve or sFliC1sera (1:300). STm
(OD600 1.4) was injected into the agar and swim zone diameters
measured after overnight incubation at room temperature.
Flagellin-specific ELISA
ELISA to detect Ab to sFliC or purified flagella was performed as
described previously [25]. Plates were coated at 5 mg/mL, then
sera, diluted 1:20 in PBS, was added and diluted stepwise.
Primary antibodies were detected using alkaline phosphatase-
conjugated, goat anti-mouse antibodies (Southern Biotech), and
Sigma-Fast p-nitrophenylphosphate. Relative reciprocal titres
were calculated by measuring the dilution at which the serum
reached a defined OD405.
FACS analysis, cell sorting, and the generation of
chimeras
Splenic single-cell suspensions were prepared and red cells lysed
with ammonium chloride buffer. Sometimes, cells were CFSE-labeled
by resuspension at 5 107 cells/mL in 5 mM CFSE for 5 min. Cells
were blocked with anti-CD16:CD32 before staining with one or more
of: CD3-FITC, CD62L-phycoerythcin, CD4-allophycocyanin (APC)
(all eBioscience) and CD4-PerCP Cy 5.5 and CD69 (biotinylated; BD
Biosciences). SM1 cells were identified using CD45.1-phycoerythcin
(eBioscience) or vb2-biotin and SA-PerCP Cy 5.5 (BD Biosciences) or
CFSE dilution. Samples were acquired on a FACScalibur cytometer
and the data were analyzed using FlowJo Software.
Intracellular cytokine staining for IFN-g and T-bet was
performed by ex-vivo restimulation [37]. Briefly, 2.5 107 sple-
nocytes/mL stimulated with purified anti-CD3 (precoated over-
night at 10mg/mL) or sFliC (1mg/mL) in the presence of 1mg/mL
anti-CD28. Cells were incubated at 371C for 2.5 h, followed by
2.5 h with GolgiStop. Cells were then surface-stained (CD3, CD4,
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2011. 41: 1606–1618 Immunity to infection 1615
and CD62L), fixed and permeabilized with Cytofix/Cytoperm Plus
and intracellular staining performed using anti-T-bet-PE (Santa
Cruz) or anti-IFN-g-APC or irrelevant APC-labeled isotype control.
Chimeras were generated through i.p. transfer of total spleno-
cytes (107) in 200mL PBS from SM1 or OTII BoyJ mice into WT or
Rag1-deficient recipients. Sometimes, splenocytes were first labeled
with CFSE or CD41 T cells sorted (Z98% purity) using a MoFlo cell
sorter before 2105 cells were transferred i.p. into Rag1-deficient
mice. Chimeras were immunized or infected 24 h post-transfer.
ELISPOT for the detection of FliC-specific IFN-c- or IL-4-
secreting SFC
ELISPOT assay for IFN-g was performed using anti-mouse IFN-g
antibody (XMG 1.2) [42] as capture Ab and biotin anti-mouse
IFN-g for detection. ELISPOT for IL-4 was performed with a
mouse IL-4 ELISPOT kit (anti-IL4 16-7041-68; eBioscience). After
coating with capture Ab, plates were blocked before adding
4 105 splenocytes per well. Cells were either restimulated
(5 mg/mL sFliC or medium) with 1 mg/mL of anti-CD28, for 48 h
at 371C before incubation for 2 h at room temperature with
biotinylated anti-IL4 (BVD6-24G2) or anti-IFN-g. Streptavidin-
peroxidase was added and signal detected using DAB. Spots
counted using an AID ELISPOT Reader and software. Counts
were expressed as SFC/4105 splenocytes.
Quantification of gene expression
RT-PCR was performed on flow cytometry sorted T cells (2 105
cells at Z98% purity) subdivided into effector and naı¨ve
populations (based on CD62L expression). In mixed SM1-WT
chimeras, SM1 cells were identified based on CFSE or Vb2 staining.
RNA was purified using the RNeasy Mini Kit (Qiagen) and reverse
transcribed using Superscript III. Real-time PCR for relative gene
expression was performed as described previously [25, 63, 66]
using 2 PCR Master Mix (Applied Biosystems) and the results
presented as the relative signal per cell compared with b-actin.
Statistical analysis
Statistical analysis was conducted using the Mann–Whitney
nonparametric sum of ranks test using the Analyze-It programme
and significance was accepted where pr0.05.
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